Nick Paul Taylor

Biography for Nick Paul Taylor

Nick Taylor, UK Correspondent

Nick Taylor is a freelance journalist with more than six years' experience of reporting on the global biopharma industry. Since graduating with a biology degree from the University of York, Nick has written for numerous healthcare publications, including Nature BioPharma Dealmakers, Life Science Leader and Outsourcing-Pharma. You can contact him at and follow him on Twitter at @NickPaulTaylor.

Articles by Nick Paul Taylor

GSK is refusing to write off its cancer vaccine despite last year's PhIII flop

GlaxoSmithKline's MAGE-A3 cancer vaccine was viewed as a long shot by some analysts even before it missed its first co-primary endpoint last year. Yet while analysts lowered expectations in the wake of the weak data in melanoma patients, GSK is continuing to promote its prospects.

Circassia to test U.K. investors' appetite for risk with a $285M IPO

European financial markets have largely missed out on the biotech IPO boom, with the few local companies to go public traveling to the U.S. to file their papers. Now British vaccine developer Circassia is to test investor appetite in the United Kingdom with a bumper $285 million IPO.

Buzz: Novartis mulls selling its vaccine unit as swap deal with Merck stalls

Last week Novartis' vaccine unit posted yet another operating loss, extending its streak in the red to four years. Yet despite its well-known, long-term problems, suitors are reportedly circling the unit, with the potential of Bexsero and Menveo likely to be a factor attracting potential buyers.

Study: Merck's and GSK's HPV vaccines don't encourage risky sex

When the Centers for Disease Control and Prevention looked into the reasons behind low uptake of GlaxoSmithKline's and Merck's human papillomavirus vaccines last year, the effect of parental attitudes to sex grabbed the headlines. Yet while parents may fear the vaccine will lead to risky sex, all the evidence suggests otherwise.

CDC finds rare cases of nurses injecting GSK's and Merck's oral rotavirus vaccines

The U.S. childhood immunization schedule is overwhelmingly made up of injectables. Yet in among the vaccines for measles, mumps and other diseases are two orally delivered products--GlaxoSmithKline's and Merck's rotavirus vaccines. The rarity of oral vaccines means providers have less experience delivering them, but does this mean there are more errors?

Pfizer pins hopes on vaccine data to kick-start revenue growth

Pfizer has spent the past few years trying to turn its sprawling, expensive R&D operation into an efficient, slimmed down drug development machine. The cost cutting side has gone well. Now it needs to show the R&D team can make money too by delivering a new wave of drugs and vaccines.

Novartis: We cannot keep shipping Bexsero under investigational license

Novartis is trying to make its meningitis B vaccine Bexsero widely available in the U.S., instead of just supplying it on an ad hoc basis to tackle outbreaks.

Production problem prompts GSK to stop worldwide deliveries of chickenpox vaccines

In the almost 20 years since FDA controversially approved Merck's chickenpox vaccine, the product--as well as similar combination shots--has faced multiple shortages. GlaxoSmithKline has also struggled to maintain supply of its rival vaccines and this week warned of yet another shortage.

The U.K. is set to fall well short of flu vaccine uptake targets

Last summer the United Kingdom set primary care physicians the ambitious target of vaccinating 75% of high-risk patients against influenza. The short notice and scale of the goal--which represents a 50% increase in one winter--caused consternation among physicians who said it would take a miracle to achieve. Now it appears no miracle occurred and the U.K. will miss its target.

Survey: Anti-vaccine views have little correlation with politics

Blogs and social media chatter often paint liberals, particularly Whole Foods-shopping, "earth mother" types, as the lead proponents of the anti-vaccine movement. Yet this view has been contradicted by surveys in the past, and was once again revealed to be flawed by data published this week.